Practice questions

Heart Failure practice questions

10 heart Failure questions from the ICU Basics bank. Tap an answer to see whether you were right, with a rationale for every choice. Your score is at the end.

Questions reviewed by Alex G, BSN, RN, CEN, CCRN, CMC, NREMT-P · From the live ICU Basics bank · Study first: Heart Failure cheat sheet

Question 1 · Heart Failure & Cardiomyopathy

A 66-year-old patient is seen in the heart failure clinic 3 weeks after a first admission for HF. The echo during that admission showed an LVEF of 45% with elevated filling pressures, and no earlier echo exists. The patient takes furosemide 20 mg daily and has NYHA class II symptoms. Data are: BP 118/72 mm Hg, HR 74 in sinus rhythm, K⁺ 4.4 mEq/L, and eGFR 58 mL/min/1.73 m². Which added therapy has the STRONGEST guideline support at this stage?

  1. Start spironolactone 25 mg daily for neurohormonal blockade
  2. Start carvedilol and titrate to the HFrEF target dose
  3. Start sacubitril-valsartan, the first step in HFrEF
  4. Start an SGLT2 inhibitor such as dapagliflozin
Show the answer and rationale

Answer: D

  • A. MRAs may be considered in HFmrEF, but with a 2b recommendation; the evidence is weaker than for SGLT2 inhibitors at this EF.
  • B. β-blockers are an HFrEF pillar because of mortality trials in patients with an LVEF of 40% or less. At 45%, with no other indication such as AF or a prior MI, the evidence is weaker than for SGLT2 inhibitors.
  • C. Sacubitril-valsartan is started early in HFrEF, but in HFmrEF the ARNI, ACE inhibitors and ARBs carry only a weaker 2b recommendation, so it is not the best-supported addition.
  • D. Correct. An LVEF of 41% to 49% with no prior reduced EF is HF with mildly reduced EF. SGLT2 inhibitors carry a 2a recommendation in HFmrEF, the strongest of any drug class in this range.

The 2022 AHA/ACC/HFSA guideline sorts HF by LVEF: HFrEF 40% or less, HFmrEF 41% to 49%, HFpEF 50% or more, and HFimpEF when a prior LVEF of 40% or less has risen above 40%. Because this is a first measurement, the patient has HFmrEF, not HFimpEF, and the full HFrEF regimen is not automatically carried over. In HFmrEF, SGLT2 inhibitors have a 2a recommendation, while ARNI, ACE inhibitors, ARBs and MRAs have weaker 2b recommendations. Diuretics treat congestion as needed, and the LVEF should be re-measured, because a later value of 40% or less reclassifies the patient as HFrEF.

Sources: AHA/ACC/HFSA Heart Failure Guideline (2022)

Question 2 · Heart Failure & Cardiomyopathy

A 79-year-old who has never had lung disease has woken at night short of breath three times this week. The therapist hears expiratory wheezes throughout both lungs and fine crackles at both bases. The jugular veins are distended to the angle of the jaw while sitting upright, and both ankles have pitting edema. The nurse asks for an albuterol order for 'new asthma.' What do the findings MOST suggest?

  1. Community-acquired pneumonia in both lower lobes
  2. A first exacerbation of undiagnosed COPD
  3. Adult-onset asthma triggered by a viral infection
  4. Wheezing caused by heart failure with congestion
Show the answer and rationale

Answer: D

  • A. Pneumonia causes crackles, but with focal signs of consolidation such as egophony and decreased breath sounds, usually with fever; it does not raise the jugular venous pressure or cause leg edema.
  • B. COPD also causes wheeze, but it usually follows a long smoking or exposure history, and it would not account for distended neck veins with fine bibasilar crackles and new edema.
  • C. Wheezing most often suggests asthma, which is why the nurse thought of it, but asthma does not explain the crackles, neck vein distention and edema, and there is no history of airway disease.
  • D. Correct. Paroxysmal nocturnal dyspnea, bibasilar crackles, distended neck veins and pitting edema are heart failure findings, and wheezing can occur in heart failure as well as in airway disease.

Wheezing suggests asthma or COPD, but it can occur with other processes, including left heart failure, so the sound alone does not establish airway disease. The pattern around it decides: orthopnea or paroxysmal nocturnal dyspnea, crackles, distended neck veins and pitting edema of the legs all point to heart failure, and crackles suggest left heart failure, interstitial disease or, with consolidation, pneumonia. The therapist should share the assessment with the team so that heart failure is evaluated, for example with a natriuretic peptide level, chest radiograph and echocardiogram, because a bronchodilator would not treat the congestion.

Sources: Merck Manual Professional: Dyspnea (2025)

Question 3 · Heart Failure & Cardiomyopathy

A 74-year-old with acute cardiogenic pulmonary edema was intubated 10 minutes ago, and pink, frothy fluid keeps rising into the endotracheal tube. He is on volume control with VT 450 mL (6 mL/kg PBW), rate 18/min, PEEP 5 cm H₂O and FiO₂ 1.0. Data are: SpO₂ 84%, BP 162/94 mm Hg, equal breath sounds with crackles throughout, plateau pressure 24 cm H₂O. What should the therapist do FIRST?

  1. Suction the tube repeatedly until the frothy fluid stops
  2. Increase the tidal volume to 8 to 10 mL/kg to recruit the flooded alveoli
  3. Raise the PEEP in steps toward 10 to 12 cm H₂O
  4. Change to pressure control with an inverse I:E ratio
Show the answer and rationale

Answer: C

  • A. Clearing the tube looks urgent, but repeated suctioning drops the PEEP each time, derecruits the lungs and worsens the hypoxemia, and the edema fluid keeps re-forming; suction when fluid blocks the tube.
  • B. Larger breaths can open some alveoli, which makes this tempting, but they raise plateau pressure and injure the lung, and the alveoli collapse again at end-expiration because the PEEP is unchanged.
  • C. Correct. Higher PEEP holds flooded alveoli open, raises the PaO₂ and lowers LV preload and afterload; his blood pressure leaves room for it.
  • D. Inverse ratio ventilation raises mean airway pressure, but it is a rescue mode for refractory ARDS that needs deep sedation and can drop cardiac output; a simple PEEP increase comes first.

Cardiogenic pulmonary edema floods alveoli with fluid that is pushed up the airway as froth. Positive pressure helps in two ways: PEEP raises alveolar pressure, keeps fluid-filled units open and improves oxygenation, and the rise in intrathoracic pressure reduces venous return and LV afterload, which suits a hypertensive, congested heart. While the team gives IV nitrates and a loop diuretic, the therapist titrates PEEP and FiO₂ to the saturation, watches blood pressure with each step, and suctions only when fluid obstructs the tube, using closed suction to avoid losing PEEP.

Sources: Pilbeam's Mechanical Ventilation, 8th ed.; Merck Manual, Professional Version; AARC CPG: Artificial Airway Suctioning (2022)

Question 4 · Heart Failure & Cardiomyopathy

A 69-year-old with COPD (FEV₁ 52% of predicted) and heart failure with reduced ejection fraction (LVEF 35%) calls his pulmonary rehabilitation respiratory therapist. Over 4 days he has become more breathless on stairs and now sleeps on three pillows, and his ankles are swollen. His home weight log has risen from 81.0 to 83.4 kg. His cough is unchanged, and his sputum is the usual small amount of white mucus. He is comfortable at rest, speaks in full sentences, and his home oximeter reads 94%. His COPD action plan includes a standby prednisone and antibiotic pack. What should the therapist advise?

  1. Contact his heart failure team today about a diuretic change
  2. Double his albuterol and call back in 48 hours if he is no better
  3. Limit his fluids to 1 L a day until his weight comes back down
  4. Start the standby prednisone and antibiotic pack today
Show the answer and rationale

Answer: A

  • A. Correct. A gain of about 2.4 kg (5 lb) in 4 days with orthopnea and ankle edema meets the heart failure reporting threshold, so the team should review his diuretic now.
  • B. A bronchodilator increase is a safe first step for wheezing, which makes this tempting, but it does not treat fluid overload, and waiting 2 days lets the congestion progress.
  • C. Cutting fluids sounds like sensible self-care for weight gain, but fluid restriction is used only when prescribed, and it does not replace the diuretic adjustment the gain calls for.
  • D. More breathlessness in a patient with COPD is the usual trigger for the standby pack, but antibiotics are for more purulent sputum with more dyspnea or volume, and his sputum is unchanged while the weight, orthopnea and edema point to congestion.

Heart failure is one of the conditions that mimic a COPD exacerbation and must be ruled out before treating one; others are pneumonia, pneumothorax, arrhythmia and pulmonary embolism. Heart failure teaching asks patients to weigh themselves each morning after voiding and to report a gain of 2 to 3 lb in a day or 5 lb in a week, or new dyspnea or swelling. His weight has risen about 5 lb in 4 days with orthopnea and edema, while his sputum is unchanged, so congestion is the likely cause and a diuretic change is the treatment. Fluids are restricted only when prescribed.

Sources: AHA/ACC/HFSA Heart Failure Guideline (2022); GOLD COPD Report (2026)

Question 5 · Heart Failure & Cardiomyopathy

Six months after a large anterior MI, a patient has refractory heart failure and recurrent monomorphic VT. Echocardiography shows an anteroapical LV aneurysm with paradoxical systolic bulging, and the patient is scheduled for surgical ventricular restoration (Dor procedure). The PRIMARY hemodynamic goal of this surgery is to:

  1. Restore blood flow to the aneurysmal segment
  2. Lower RV afterload by reducing pulmonary pressures
  3. Increase end-diastolic volume to boost stroke volume
  4. Reduce end-systolic volume and restore elliptical shape
Show the answer and rationale

Answer: D

  • A. An aneurysm is transmural scar with no viable muscle to revascularize.
  • B. Pulmonary pressures may improve secondarily, but the primary target is LV geometry.
  • C. The goal is to reduce volume. A dilated LV has high wall stress and inefficient ejection.
  • D. Correct. Excluding the dyskinetic scar lowers wall stress (Laplace) and improves ejection efficiency.

A dyskinetic LV aneurysm bulges outward during systole and absorbs energy that should eject blood. It enlarges the ventricle, raising wall stress (Laplace’s law: tension ∝ pressure × radius), and serves as a substrate for reentrant VT. Surgical ventricular restoration excludes the scar with a patch, reduces end-systolic volume, and restores a more elliptical shape, often with endocardial ablation of the VT substrate. After surgery the smaller LV may have restrictive filling, so the nurse should watch for low output with elevated filling pressures.

Sources: Hardin & Kaplow, Cardiac Surgery, 4th ed.; Bojar, Cardiac Surgery Periop Care, 6th ed.

Question 6 · Heart Failure & Cardiomyopathy

A patient with chronic HFrEF who takes carvedilol 25 mg twice daily is admitted with ADHF. The patient has warm extremities, BP 124/76 mm Hg, HR 88/min, lactate 1.3 mmol/L, and crackles with 3+ edema. Which plan for the carvedilol is MOST appropriate?

  1. Switch it to an IV metoprolol infusion for tighter rate control
  2. Continue it; lower the dose only for hypotension or low output
  3. Stop it until the patient is euvolemic and ready for discharge
  4. Double the dose to slow the heart rate during diuresis
Show the answer and rationale

Answer: B

  • A. A switch is unnecessary and risks overshooting in acute HF.
  • B. Correct. Continuing β-blockers in warm-and-wet ADHF is recommended, because stopping them is linked to worse outcomes.
  • C. Routine discontinuation in a well-perfused patient is associated with higher mortality and readmission.
  • D. Uptitration is avoided during active decompensation.

In ADHF with adequate perfusion, current guidance supports continuing chronic β-blocker therapy, with a dose reduction only for hypotension, bradycardia, or signs of low output. Stopping β-blockers has been associated with higher in-hospital and post-discharge mortality. β-blockers are held in cardiogenic shock or significant hypoperfusion and restarted cautiously once the patient stabilizes.

Sources: AHA/ACC/HFSA Heart Failure Guideline (2022); ACC Hospitalized HF Decision Pathway (2024); Jacobson, CV Nursing Practice, 3rd ed.

Question 7 · Heart Failure & Cardiomyopathy

A patient with low-output heart failure (CI 1.7 L/min/m², cool extremities) has an order for milrinone 50 mcg/kg IV over 10 minutes, then 0.375 mcg/kg/min. BP is 88/50 mm Hg (MAP 63 mm Hg) and HR 104/min. Which action is MOST appropriate?

  1. clarify the loading dose before giving it.
  2. give the bolus and the infusion as ordered.
  3. give the bolus over 30 minutes instead.
  4. start norepinephrine before giving the bolus.
Show the answer and rationale

Answer: A

  • A. Correct. Milrinone's vasodilation can drop BP, and a loading dose in a patient whose MAP is already 63 risks hypotension, so many clinicians start the maintenance infusion without it.
  • B. Tempting because the cardiac index is very low and the dose is standard, but the low BP makes the bolus the riskiest part of the order.
  • C. Tempting because slowing a bolus usually softens its effect, but it still delivers the full load to a hypotensive patient and changes an order without the prescriber.
  • D. Tempting because a vasopressor could offset the vasodilation, but adding a second drip to make a bolus possible is a prescriber decision and not the first step.

Milrinone is a phosphodiesterase-3 inhibitor that raises contractility and dilates arteries and veins. The label warns that it may produce hypotension through this vasodilator effect and says to reduce or stop the drug until the patient stabilizes. Hypotension is dose dependent, and the 50 mcg/kg load gives the highest early drug level; even an infusion-only regimen caused sustained hypotension needing treatment in about 11% of patients in the OPTIME-CHF trial. So with a systolic BP of 88 and a MAP of 63 the nurse clarifies whether to omit the bolus and start the 0.375 mcg/kg/min infusion alone. Continuous ECG monitoring is needed for ventricular arrhythmias, and the rate is reduced in renal impairment.

Sources: StatPearls (NCBI Bookshelf); FDA Prescribing Information (DailyMed); Milrinone Lactate Injection Prescribing Information (Hospira); OPTIME-CHF: Short-Term IV Milrinone in Heart Failure (JAMA 2002)

Question 8 · Heart Failure & Cardiomyopathy

A 54-year-old patient with nonischemic dilated cardiomyopathy had an LVEF of 25% two years ago. On sacubitril-valsartan, carvedilol, spironolactone, and dapagliflozin, the LVEF is now 55%. The patient is asymptomatic at a clinic visit and asks to stop the heart failure medicines. Which response is MOST accurate?

  1. Keep carvedilol and stop the other three medicines
  2. Taper one drug at a time with serial echoes
  3. Stop the medicines, since the patient now has HFpEF
  4. Continue the current regimen to prevent relapse of LV dysfunction
Show the answer and rationale

Answer: D

  • A. Partial withdrawal still removes the drugs that reversed remodeling. There is no evidence that a β-blocker alone prevents relapse.
  • B. This sounds cautious, but in the trial that tested phased withdrawal (TRED-HF) about 44% relapsed within 6 months.
  • C. A prior LVEF of 40% or less with a later value above 40% is HF with improved EF, not HFpEF. The improvement reflects therapy, not cure.
  • D. Correct. This is HF with improved EF, and the guideline recommends continuing GDMT even when asymptomatic, because withdrawal often leads to recurrent LV dysfunction.

The 2022 AHA/ACC/HFSA guideline defines HF with improved EF (HFimpEF) as a prior LVEF of 40% or less with a follow-up LVEF above 40%. In the TRED-HF trial, 44% of patients with recovered dilated cardiomyopathy relapsed within 6 months of stopping therapy, so GDMT should be continued even in asymptomatic patients. Recovery of EF reflects remission, and the underlying myocardial disease remains, which is why the patient stays in the HF category.

Sources: AHA/ACC/HFSA Heart Failure Guideline (2022); ACC HFrEF Decision Pathway (2024)

Question 9 · Heart Failure & Cardiomyopathy

A 68-year-old with COPD (FEV₁ 46% of predicted) and heart failure with reduced ejection fraction (LVEF 28%) is admitted with a COPD exacerbation. He takes bisoprolol 5 mg daily, sacubitril-valsartan, spironolactone and dapagliflozin. After three albuterol-ipratropium treatments he still has diffuse wheezes. Data are: HR 86/min, BP 118/72 mm Hg, RR 24/min, SpO₂ 91% on 2 L/min. A resident wants to stop the bisoprolol until the wheezing settles. What should the respiratory therapist recommend?

  1. Switch to metoprolol tartrate twice daily
  2. Hold the beta-blocker for 48 hours, then restart it
  3. Continue the bisoprolol and treat the exacerbation
  4. Switch to carvedilol, which has strong HFrEF evidence
Show the answer and rationale

Answer: C

  • A. Metoprolol tartrate is beta-1 selective, which makes it look airway-friendly, but only the succinate form, carvedilol and bisoprolol have proven benefit in HFrEF, so the switch would trade a proven drug for an unproven one.
  • B. A short hold sounds cautious, but stopping a beta-blocker abruptly in heart failure risks rebound tachycardia and decompensation, and a selective agent at this dose is not what is driving the wheezes.
  • C. Correct. Bisoprolol is a beta-1-selective blocker with proven survival benefit in heart failure with reduced ejection fraction. GOLD says such patients should not be denied a beta-blocker, and the exacerbation is treated as usual.
  • D. Carvedilol does have outcome data in HFrEF, but it is nonselective and also blocks beta-2 receptors in the airways, so moving from bisoprolol to carvedilol during bronchospasm is a step in the wrong direction.

GOLD 2026 states that beta-1-blockers improve survival in heart failure and are recommended in patients who also have COPD, that patients with COPD should not be denied a beta-blocker when there is a cardiovascular indication, and that comorbid disease is treated as usual despite COPD. Selective agents are not used to prevent exacerbations in patients without a cardiac indication. In HFrEF the beta-blocker is one of four pillars with an ARNi, a mineralocorticoid antagonist and an SGLT2 inhibitor, and only bisoprolol, carvedilol and metoprolol succinate are proven. Persistent wheeze calls for adding systemic steroids and reviewing for infection or edema, not stopping cardiac therapy.

Sources: GOLD COPD Report (2026); AHA/ACC/HFSA Heart Failure Guideline (2022)

Question 10 · Heart Failure & Cardiomyopathy

A patient with ischemic cardiomyopathy (EF 30%) was hospitalized for HF 6 months ago. Now on GDMT, the patient is comfortable at rest but becomes short of breath walking briskly up one flight of stairs or carrying groceries. How is this patient classified?

  1. ACC/AHA stage D, NYHA class III
  2. ACC/AHA stage B, NYHA class II
  3. ACC/AHA stage C, NYHA class II
  4. ACC/AHA stage C, NYHA class IV
Show the answer and rationale

Answer: C

  • A. Stage D is advanced HF refractory to therapy, and class III means symptoms with less than ordinary activity.
  • B. Stage B is structural disease without prior or current HF symptoms.
  • C. Correct. Structural disease with prior HF symptoms is stage C, and symptoms with ordinary activity are NYHA class II.
  • D. Class IV means symptoms at rest or with any activity.

ACC/AHA stages describe disease progression and do not move backward: stage A (at risk), B (structural disease without symptoms), C (structural disease with current or prior HF symptoms), and D (advanced HF refractory to therapy). NYHA classes describe current functional limitation and can change: class I (no limitation), II (symptoms with ordinary activity), III (symptoms with less than ordinary activity), and IV (symptoms at rest). A patient with a prior HF admission remains stage C even when symptoms improve.

Sources: AHA/ACC/HFSA Heart Failure Guideline (2022); Jaski, The 4 Stages of Heart Failure (2015)

Practice this in the app

These 10 are a sample. ICU Basics has 78 heart Failure questions, and it keeps your score, explains every choice and brings back the ones you miss. No ads. Pro is coming in January 2027.

Practice 78 questions in your browser

Download on theApp StoreGet it onGoogle Play

Study the topic

More practice questions

Sample questions by exam